Concord Biotech Limited (CONCORDBIO) — share transfer | 6 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Concord Biotech Limited received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming dematerialized securities were processed and updated in depositories during the reporting period.

📄 View Original Announcement (PDF)

About Concord Biotech Limited (CONCORDBIO)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹15,212.77 Cr P/E: 55.7 ROE: 13.5% ROCE: 18.1% Div Yield: 0.52%

View full CONCORDBIO stock details →

📡 Get AI alerts when CONCORDBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CONCORDBIO — Free

📊 More CONCORDBIO filings

See all CONCORDBIO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CONCORDBIO files new disclosures

Track CONCORDBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CONCORDBIO — Free

Free account · 2 AI queries/day